arrow
G

Gaetano Facchini

santa maria delle grazie hospital
H指数:44
被引数:6,758

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study

相对剂量强度对肌肉浸润性尿路上皮癌新辅助化疗中病理完全缓解的影响:一项多中心回顾性研究

2026-07-020
OAAI
Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis

根治性前列腺切除术后生化复发患者的挽救性放射治疗联合或不联合激素治疗:一项系统评价和Meta分析

2026-05-180
OAAI
Cancer in migrant populations: evidence from a regional oncology network

移民人群中的癌症:区域性肿瘤网络证据

2026-04-090
OAAI
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study

同源重组修复基因检测变量及前列腺癌患者的诊断路径:一项多中心队列研究

2025-12-010
PRE
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort

在铂类化疗和帕博利珠单抗治疗后的转移性尿路上皮癌中恩沃利单抗维得尼单抗的疗效:ARON-2EV队列的多中心真实世界分析

2025-11-030
OAAI
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study

177Lu-PSMA 与 cabazitaxel 在去势抵抗性前列腺癌患者中的真实世界疗效与安全性数据:ARON-3 研究结果

2025-09-120
PREAI
Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies

将BRCA检测纳入常规前列腺癌护理: SIUrO和其他意大利科学学会的多学科方法

2025-01-230
OAAI
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
2024-10-011
OA
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

转移性尿路上皮癌患者铂类化疗和Avelumab维持后的Enfortumab Vedotin: 来自ARON-2EV研究的回顾性数据

2024-10-011
OAAI
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

BRCA1/2致病性变异位点与转移性去势抵抗性前列腺癌患者从PARP抑制剂中获益的关系:PROGRESS研究的结果

2024-09-010
PRE
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

一线免疫疗法联合或酪氨酸激酶抑制剂治疗转移性非透明细胞肾细胞癌的前期细胞减灭性肾切除术对现实世界的影响 (来自ARON-1回顾性研究的亚分析)

2024-05-054
OAAI